Sabatini and Associates, LLC

On behalf of his client, Attorney James Sabatini has filed a product liability lawsuit against the manufacturers of Yasmin in Connecticut Federal District Court. The lawsuit alleges that the birth control medication Yasmin was a substantial factor in causing the client to suffer bilateral pulmonary emboli.  Sabatini and Associates, LLC represents women in Yasmin and Yaz product liability litigation and is presently accepting Yasmin and Yaz cases.

The Firm has been retained by a woman who has bladder cancer to investigate whether Actos caused her cancer. Our client had been taking Actos for more than one year before being diagnosed with bladder cancer. Recent reports have indicated a potential connection between Actos and bladder cancer.  France has suspended the use of Actos and Germany no longer recommends that new patients be prescribed Actos.

The diabetes drug Actos has been linked to bladder cancer.  A lawsuit has already been filed in court against Takeda Pharmaceuticals claiming that its diabetes medication Actos caused the plaintiff’s bladder cancer.  In the lawsuit, the plaintiff alleges that Takeda failed to warn of the risks of bladder cancer connected with Actos and that had there been such a warning the plaintiff would have sought an alternative course of treatment. 

Recent studies have indicated a connection between Actos usage and an increased likelihood of bladder cancer.  The FDA studied data from the first five years of a 10 year Actos safety study begun in 2002 and concluded that risk of bladder cancer was 40 percent higher for patients taking Actos for at least one year.  Doctors in France and Germany have been advised to stop prescribing Actos. If you or a loved one has taken Actos for more than one year, you may have a claim for damages and should contact our attorneys today.

Xanodyne Pharmaceuticals Inc. the maker of Darvon and Darvocet, the brand version of the prescription pain medication propoxyphene, has agreed to withdraw the medication from the U.S. market at the request of the U.S. Food and Drug Administration. The FDA also informed the generic manufacturers of propoxyphene-containing products of Xanodyne’s decision and requested that they voluntarily remove their products as well. The FDA sought market withdrawal of propoxyphene after receiving new clinical data showing that the drug puts patients at risk of potentially serious and even fatal heart rhythm abnormalities. As a result of the data and other information, the FDA decided that the risks of the medication outweigh the benefits. Studies show that, even when taken at recommended doses, propoxyphene causes significant changes to the electrical activity of the heart. These changes, which can be seen on an electrocardiogram (ECG), can increase the risk for serious abnormal heart rhythms that have been linked to serious adverse effects, including sudden death. The available data also indicate that the risk of adverse events for any particular patient (even patients who have taken the drug for many years) is subject to change based on small changes in the health status of the patient, such as dehydration, a change in medications, or decreased kidney function.

On October 13, 2010 Judge David Herndon, who is presiding over the federal court YAZ and Yasmin MDL, ordered trial dates for bellwether trials.  The order further identified the order of the three bellwether trials, the dates of the trials, and the claimed injury in the cases.  The schedule is set forth below.

1. The first trial is set September 12, 2011. This will be a pulmonary embolism (PE) case.

2. The second trial is set January 9, 2012. This will be a gallbladder (GB) case.

3. The third trial is set April 2, 2012. This will be an additional thromboembolic (VTE) case.